Alivus Life Sciences reported net income to company of 4.417 B for the latest twelve months ending December 31, 2024 on its income statement.
The tables below summarizes Alivus Life Sciences’s Net Income to Company and common size over the last five years:
| Fiscal Year | Net Income to Company | Revenue | % Revenue |
|---|
| 2020-03-31 | 3.131 B | 15.373 B | 20.4% |
| 2021-03-31 | 3.516 B | 18.852 B | 18.6% |
| 2022-03-31 | 4.187 B | 21.232 B | 19.7% |
| 2023-03-31 | 4.67 B | 21.612 B | 21.6% |
| 2024-03-31 | 4.709 B | 22.832 B | 20.6% |
The tables below summarizes Alivus Life Sciences’s Net Income to Company and common size over the last four quarters:
| Quarter Ending | Net Income to Company | Revenue | % Revenue |
|---|
| 2024-03-31 | 979.4 M | 5.366 B | 18.3% |
| 2024-06-30 | 1.115 B | 5.886 B | 18.9% |
| 2024-09-30 | 953.2 M | 5.069 B | 18.8% |
| 2024-12-31 | 1.37 B | 6.418 B | 21.3% |
Click the link below to download a spreadsheet with an example Net Income to Company calculation for Alivus Life Sciences Ltd below: